Pablo Penaloza‐MacMaster

This study develops a polymer-lipid hybrid nanoparticle (PLNP) to enhance mRNA delivery and T cell immunity, showing improved antigen-specific T cell responses and protection against viral variants and cancer.

This study identifies mAbs targeting HCoV-HKU1 spike protein and shows that receptor-binding site recognition alone does not predict neutralization in primary cells.

This paper develops an mRNA vaccine against OC43, a common cold coronavirus, showing cross-protection against related viruses like MHV-A59.

This study compares the immunological profiles and protective efficacy of Ad5, mRNA, and protein vaccines in mice, showing differences in antigen kinetics, immune responses, and performance based on serostatus and dosing regimen.

This study compares antibody responses after homologous and heterologous boosting in mice, finding that protein-based boosters elicit stronger antibody responses than Ad5-based boosters.

This study shows that administering 4-1BB costimulatory antibodies after 96 hours post-mRNA vaccination enhances CD8 T cell responses and protection against breakthrough infections.

This study shows that replication-attenuated r3LCMV vectors enhance tumor control and survival in multiple tumor models, including immunodeficient mice, through IFN-I signaling.

This study compares immune responses and metabolism in SARS-CoV-2 and HIV-1 infections using single-cell transcriptomics, identifying shared and distinct features in 94,442 PBMCs from 16 patients.